TG Therapeutics (TGTX) Stock Price
TG Therapeutics Price
Revenue has compounded at 122.3% per year over the past 13 years to 616.29 M USD. Earnings per share have declined at 10.1% per year over the last 15 years. TG Therapeutics's net margin stands at 72.6%, up from -5,204.1% several years earlier. Analysts set a median price target of 80.50 USD, implying 43.8% above the current price. Of 14 analysts, 12 rate the stock a buy — an overall Buy consensus. The stock trades about 108% above its 52-week low.
TG Therapeutics stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of TG Therapeutics over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how TG Therapeutics stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing TG Therapeutics's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | TG Therapeutics Price |
|---|---|
| 9/23/2026 | 56.00 USD |
| 9/22/2026 | 57.54 USD |
| 9/21/2026 | 57.79 USD |
| 9/18/2026 | 56.37 USD |
| 9/17/2026 | 56.47 USD |
| 9/16/2026 | 54.93 USD |
| 9/15/2026 | 53.08 USD |
| 9/14/2026 | 53.80 USD |
| 9/11/2026 | 54.19 USD |
| 9/10/2026 | 55.39 USD |
| 9/9/2026 | 54.65 USD |
| 9/8/2026 | 55.38 USD |
| 9/4/2026 | 55.99 USD |
| 9/3/2026 | 56.71 USD |
| 9/2/2026 | 56.90 USD |
| 9/1/2026 | 56.09 USD |
| 8/31/2026 | 54.30 USD |
| 8/30/2026 | 53.52 USD |
| 8/28/2026 | 54.94 USD |
| 8/27/2026 | 55.02 USD |
| 8/26/2026 | 55.03 USD |
| 8/25/2026 | 55.42 USD |
| 8/24/2026 | 54.56 USD |
| 8/21/2026 | 54.27 USD |
| 8/20/2026 | 50.56 USD |
| 8/19/2026 | 50.94 USD |
| 8/18/2026 | 49.59 USD |
| 8/14/2026 | 48.74 USD |
| 8/13/2026 | 47.94 USD |
| 8/12/2026 | 49.50 USD |
TG Therapeutics Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
TG Therapeutics Income Statement, Balance Sheet, Cash Flow Statement
| REVENUEB USD |
|---|
| REVENUE GROWTH% |
| GROSS MARGIN% |
| GROSS INCOMEB USD |
| EBITB USD |
| EBIT MARGIN% |
| NET INCOMEM USD |
| NET INCOME GROWTH% |
| SHARESM |
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026e | 2027e | 2028e | 2029e | 2030e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | – | – | – | – | 0.01 | – | 0.23 | 0.33 | 0.62 | 0.96 | 1.32 | 1.62 | 1.90 | 2.23 |
| – | – | – | – | – | – | – | -66.67 | 11,550.00 | 41.20 | 87.23 | 55.36 | 37.72 | 23.14 | 17.31 | 17.17 |
| – | – | – | – | – | – | 83.33 | 100.00 | 93.99 | 88.15 | 83.60 | 83.60 | 83.60 | 83.60 | 83.60 | 83.60 |
| 0.52 | 0.52 | 0.52 | 0.52 | 0.52 | 0.52 | 0.01 | – | 0.22 | 0.29 | 0.52 | 0.80 | 1.10 | 1.36 | 1.59 | 1.87 |
| -0.06 | -0.08 | -0.12 | -0.17 | -0.17 | -0.27 | -0.34 | -0.21 | 0.02 | 0.04 | 0.12 | 0.21 | 0.56 | 0.68 | 0.89 | 1.12 |
| – | – | – | – | – | – | -5,700.00 | -10,650.00 | 8.58 | 12.46 | 19.97 | 22.05 | 42.56 | 41.96 | 46.59 | 50.02 |
| -62.00 | -78.00 | -118.00 | -173.00 | -172.00 | -279.00 | -348.00 | -223.00 | 12.00 | 23.00 | 447.00 | 159.00 | 454.00 | 582.00 | 673.00 | 851.00 |
| 12.73 | 25.81 | 51.28 | 46.61 | -0.58 | 62.21 | 24.73 | -35.92 | -105.38 | 91.67 | 1,843.48 | -64.43 | 185.53 | 28.19 | 15.64 | 26.45 |
| 48.13 | 49.28 | 66.57 | 81.17 | 95.66 | 124.10 | 132.56 | 137.11 | 143.09 | 160.24 | 159.37 | 159.37 | 159.37 | 159.37 | 159.37 | 159.37 |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales TG Therapeutics generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue TG Therapeutics retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare TG Therapeutics's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares TG Therapeutics has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against TG Therapeutics's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
TG Therapeutics stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
TG Therapeutics Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
TG Therapeutics business model & stock analysis
TG Therapeutics SWOT Analysis
Strengths
1. Strong Pipeline: TG Therapeutics Inc maintains a robust pipeline of potential therapeutics, demonstrating their dedication to research and development.
2. Innovative Approach: The company adopts innovative approaches to develop novel therapies, contributing to their competitive advantage in the pharmaceutical industry.
3. Experienced Team: TG Therapeutics Inc is supported by a highly skilled and experienced management team, allowing for effective decision-making and strategic planning.
Weaknesses
1. Dependence on Key Products: The company's success heavily relies on the performance of a few key products in their portfolio. Any setbacks or regulatory issues concerning these products could negatively impact their financial stability.
2. Limited Market Presence: TG Therapeutics Inc may face challenges in establishing a strong market presence, as they operate in a highly competitive industry dominated by larger pharmaceutical companies.
3. Financial Constraints: The company's financial resources may limit their ability to fully explore and develop certain research opportunities, potentially hindering their growth and innovation.
Opportunities
1. Growing Demand for Innovative Therapies: The increasing demand for groundbreaking therapies presents TG Therapeutics Inc with an opportunity to capitalize on their innovative drug candidates and gain a significant market share.
2. Strategic Partnerships: Collaborating with established pharmaceutical companies or research institutions can provide TG Therapeutics Inc with additional resources, expertise, and opportunities for expansion.
3. Mergers and Acquisitions: The company could explore potential mergers or acquisitions to enhance their product portfolio, accelerate development timelines, or access new markets.
Threats
1. Stringent Regulatory Environment: The pharmaceutical industry is subject to strict regulations, which may delay or impede TG Therapeutics Inc's product development process, leading to increased costs and potential market entry barriers.
2. Patent Expirations: The expiration of key patents for competitor products may increase market competition and affect the pricing and demand for TG Therapeutics Inc's offerings.
3. Clinical Trial Risks: The company faces the inherent risks associated with clinical trials, such as unexpected adverse events or failure to demonstrate efficacy, which could negatively impact their reputation and financial performance.
TG Therapeutics Employees
3 Years
5 Years
10 Years
25 Years
Max
Details
TG Therapeutics Eulerpool Fair Value
Details
Fair Value Estimate
ⓘWhat Is Fair Value?
Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.
Earnings-Based Fair Value
Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.
Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021
Revenue-Based Fair Value
Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"
Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021
Dividend-Based Fair Value
Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.
Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021
How to Use This Chart
When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.
TG Therapeutics historical P/E ratio, EBIT multiple, and P/S ratio
TG Therapeutics annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down TG Therapeutics's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in TG Therapeutics's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare TG Therapeutics's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
TG Therapeutics shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
TG Therapeutics stock splits
Since 2003, a total of 0.00007111111111111112 shares have been converted from one TG Therapeutics share.
Current TG Therapeutics forecasts and price targets in September 2026
Analyst Price Targets 2026TG Therapeutics Analyst Rating Actions
| Date | Firm | Action | Rating | Reliability |
|---|---|---|---|---|
| 8/7/2026 | Maintained | Overweight | 53 | |
| 7/27/2026 | Maintained | Buy | – | |
| 7/13/2026 | Maintained | Buy | – | |
| 7/7/2026 | Maintained | Underperform | 60 | |
| 7/6/2026 | Maintained | Buy | – | |
| 5/27/2026 | Maintained | Buy | – | |
| 5/6/2026 | Maintained | Buy | – | |
| 2/2/2026 | Maintained | Overweight | 53 | |
| 1/15/2026 | Maintained | Neutral | 56 | |
| 11/3/2025 | Maintained | Overweight | 53 |
Eulerpool Reliability Score (0–100): measures how often a firm’s bullish or bearish calls were directionally correct three months later, blended with the average return following its calls. Every rating we record is stored permanently and scores update continuously; firms with fewer than 3 measured calls are not scored yet.
TG Therapeutics Earnings Calls
TG Therapeutics Earnings Estimates & Surprises
| Date | EPS estimate | EPS Actual | Revenue Estimate | Price reaction | Quarterly report |
|---|---|---|---|---|---|
| 11/2/2026 | 0.36USD | - | 247.06 MUSD | - | 2026 Q3 |
| 8/3/2026 | 0.31USD | 0.05USD | 229.77 MUSD | - | 2026 Q2 |
| 5/6/2026 | 0.23USD | 0.14USD | 200.33 MUSD | - | 2026 Q1 |
| 2/26/2026 | 0.35USD | 0.14USD | 191.79 MUSD | - | 2025 Q4 |
| 11/3/2025 | 0.24USD | 2.43USD | 193.80 MUSD | - | 2025 Q3 |
| 8/4/2025 | 0.32USD | 0.17USD | 146.27 MUSD | - | 2025 Q2 |
| 5/5/2025 | 0.18USD | 0.03USD | 134.20 MUSD | - | 2025 Q1 |
| 3/3/2025 | 0.08USD | 0.15USD | 108.80 MUSD | - | 2024 Q4 |
| 11/4/2024 | 0.03USD | 0.02USD | 98.79 MUSD | - | 2024 Q3 |
| 8/6/2024 | -0.05USD | 0.04USD | 65.89 MUSD | - | 2024 Q2 |
EESG©
Eulerpool ESG Scorecard© for the TG Therapeutics stock
EEnvironment
Environment
SSocial
Social
GGovernance (Corporate Governance)
Governance (Corporate Governance)
The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.
TG Therapeutics shareholder structure
| % | Name |
|---|---|
14.01671% | |
5.44833% | |
5.21163% | |
4.15927% | |
2.53799% | |
2.20453% |
TG Therapeutics Beneficial Ownership Filings (SEC 13D/G)
| Stake | Holder | Filing |
|---|---|---|
35.70% | SEC ↗ | |
35.70% | SEC ↗ | |
12.80% | SEC ↗ | |
11.40% | SEC ↗ | |
10.96% | SEC ↗ | |
10.96% | SEC ↗ | |
10.15% | SEC ↗ | |
7.59% | SEC ↗ | |
7.10% | SEC ↗ | |
7.10% | SEC ↗ |
TG Therapeutics Executives and Management Board
7 members · avg. age 60 · 0 % women
Mr. Michael Weiss (59)
Chairman of the Board, President, Chief Executive Officer · since 2011
18.75 M USD
Management
Mr. Sean Power (43)
Chief Financial Officer, Treasurer, Corporate Secretary
Board of Directors
Mr. Laurence Charney (78)
Lead Independent Director
Mr. Kenneth Hoberman (60)
Independent Director
Dr. Yann Echelard (61)
Independent Director
Mr. Daniel Hume (58)
Independent Director
Dr. Sagar Lonial (58)
Independent Director
Frequently asked questions about TG Therapeutics
The business model of TG Therapeutics Inc revolves around the development and commercialization of innovative biopharmaceutical products. Specializing in the field of oncology and B-cell malignancies, TG Therapeutics focuses on creating novel therapies to address the unmet medical needs of patients. By harnessing its expertise in research and development, the company aims to discover and develop targeted therapies that can improve the outcome and quality of life for individuals battling certain types of cancer. Through strategic partnerships, clinical trials, and regulatory initiatives, TG Therapeutics Inc strives to bring next-generation treatments to market, ultimately benefiting both patients and shareholders.
TG Therapeutics Inc is primarily active in the biotechnology and healthcare industries.
The main competitors of TG Therapeutics Inc in the market include pharmaceutical companies such as AbbVie Inc., Roche Holding AG, and Johnson & Johnson. These companies operate in similar therapeutic areas and have a strong presence in the market. TG Therapeutics Inc faces competition in the development and commercialization of therapies for various conditions, such as lymphoma and chronic lymphocytic leukemia.
TG Therapeutics Inc is a renowned biopharmaceutical company specializing in the development and commercialization of innovative therapies for the treatment of cancer and autoimmune diseases. Established in 1993, TG Therapeutics has emerged as a key player in the pharmaceutical industry, committed to advancing medical breakthroughs. With a focus on developing targeted therapies, the company has achieved significant milestones in its history. Over the years, TG Therapeutics has successfully introduced novel drugs and treatment options, catering to unmet medical needs. Their dedication to research and development, coupled with a strong commitment to patient care, has positioned TG Therapeutics Inc as a leading name in the healthcare sector.
TG Therapeutics Inc, a leading biopharmaceutical company, has achieved several significant milestones. Most notably, the company received accelerated approval from the U.S. Food and Drug Administration (FDA) for its innovative therapy, umbralisib, in combination with ublituximab, for the treatment of adult patients with marginal zone lymphoma (MZL) and follicular lymphoma (FL). This approval marks a major breakthrough in the field of oncology and reinforces TG Therapeutics Inc's commitment to developing effective treatments for hematologic malignancies. Additionally, the company has successfully completed various clinical trials, demonstrating the potential of its pipeline to address unmet medical needs.
TG Therapeutics Inc is primarily present in the United States. The company's headquarters are located in New York, and it focuses on the development and commercialization of novel treatments for various B-cell malignancies and autoimmune diseases. TG Therapeutics Inc primarily operates in the United States market, fostering collaborations with healthcare providers, research organizations, and regulatory authorities to advance its innovative therapies. With an unwavering commitment to improving patient outcomes, TG Therapeutics Inc continues to drive its presence and impact within the United States' healthcare landscape.
TG Therapeutics Inc represents a strong commitment to improving the lives of patients by developing innovative therapies in the field of hematological malignancies and autoimmune diseases. The company's corporate philosophy revolves around scientific excellence, patient-centricity, and collaborative partnerships. With a focus on research and development, TG Therapeutics Inc aims to bring transformative treatments to market that address unmet medical needs. Through its dedication to advancing medical science, this company strives to make a positive impact on the lives of patients, healthcare professionals, and the wider community.
Analysts currently set an average price target of 80.50 USD for the TG Therapeutics stock (median: 80.50 USD), implying +39.9 % versus the latest price. The consensus is based on 14 analyst ratings.
14 analysts currently rate the TG Therapeutics stock: 12 recommend buying, 1 holding and 1 selling. For 2026, analysts expect TG Therapeutics to generate revenue of 957.88 M USD and earnings per share of 1.00 USD.
Converted at the current exchange rate, the TG Therapeutics share trades at 49.13 EUR (56.00 USD).
The TG Therapeutics share (TGTX) is listed on 7 stock exchanges, including: NASDAQ (TGTX), London (0VGI.L), SIX (Zürich) (NKB2.SW), Frankfurt (NKB2.F), München (NKB2.MU), Düsseldorf (NKB2.DU).
TG Therapeutics Inc is a biopharmaceutical company focused on the discovery and development of innovative therapies for cancer and autoimmune diseases. The company's business model includes the development of new drugs and their marketing. The company is divided into various divisions, each focused on specific therapy areas. These divisions include both cancer therapies and immunotherapies used in autoimmune diseases. Each division is led by highly qualified researchers specialized in researching specific types of cancer and autoimmune diseases and collaborate closely to discover advanced technologies. TG Therapeutics' flagship product is the BTK inhibitor Umbralisib, used in various cancers such as lymphomas or leukemias. This drug is a particularly potent molecule specifically developed for its effect on B lymphocytes. By inhibiting these cells, the division of cancer cells is inhibited, stopping the growth of tumor cells. The medication has great potential in treating cancer patients who do not respond to other therapies. In the field of immunotherapy, the company is developing products such as Ublituximab, used in the treatment of autoimmune diseases such as multiple sclerosis. This drug inhibits the activation of B cells, reducing excessive immune reactions in patients. This leads to a decrease in the number of relapses or symptoms of autoimmune diseases and slows down the progression of the disease. TG Therapeutics follows a business-to-business model, forming partnerships with other companies to market its products. However, the company also has extensive sales and marketing capabilities to sell its products directly to hospitals and medical facilities. There is a particular focus on multiple markets, especially in the USA, Europe, and Asia. The company generates revenue through product sales and partnerships with other biotech companies. These partnerships include research agreements and licensing agreements, where the company licenses its technologies and products to other firms for fees. Thus, TG Therapeutics generates income from various revenue streams and is able to continue its research and development and expand its business. In summary, TG Therapeutics' business model is focused on the development of innovative therapies for cancer and autoimmune diseases. Through the close collaboration between researchers and developers, the company has developed a range of therapies that can be used to treat various diseases. The company aims to market its products globally to maximize its success and increase its value for patients and investors.
The expected revenue of TG Therapeutics is 957.88 M USD. This figure is based on current financial data and reflects the company's business performance.
The expected profit of TG Therapeutics is 159.29 M USD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of TG Therapeutics is currently 56.03. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the TG Therapeutics stock.
The price-to-sales ratio (P/S) of TG Therapeutics is currently 9.32. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the TG Therapeutics stock.
The Eulerpool Quality Score for TG Therapeutics is 7/10.
The ISIN of TG Therapeutics is US88322Q1085. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of TG Therapeutics is A1JXW7. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of TG Therapeutics is TGTX. The ticker symbol is used to trade TG Therapeutics shares on the stock exchange.
TG Therapeutics paid dividends every year for the past 0 years.
TG Therapeutics is assigned to the 'Health' sector.
The dividends of TG Therapeutics are distributed in USD.
TG Therapeutics stock
TG Therapeutics Peer Group
TG Therapeutics Ticker
TG Therapeutics FIGI
All fundamentals and in-depth analysis of TG Therapeutics
Our stock analysis for TG Therapeutics stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of TG Therapeutics. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.